Drug Trial Radar · NCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 28, 2026
Primary completion
Feb 23, 2033
Study completion Feb 23, 2033
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.
Conditions
- Chronic Myelogenous Leukemia
- Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Interventions
Asciminib single agentDrug
Asciminib (labelled as ABL001) administered as 40 mg tablet (adult formulation) or as 1 mg film-coated granules mini-tablets (pediatric formulation)
Primary outcomes
What the sponsor says the trial is designed to measure.
- MMR at Week 48Time frame: 48 weeks
Locations
39 sites in 17 countries. Site status is shown where the registry gives one.
Ann and Robert H Lurie Childs Hosp
Chicago, Illinois · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Columbia University Medical Center New York Presbyterian
New York, New York · Recruiting
Cinn Children Hosp Medical Center
Cincinnati, Ohio · Recruiting
Seattle Childrens Hospital
Seattle, Washington · Recruiting
Novartis Investigative Site
Brisbane, Queensland, Australia · Recruiting
Novartis Investigative Site
North Adelaide, South Australia, Australia · Recruiting
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Novartis Investigative Site
Barretos, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Edmonton, Alberta, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Tianjin, China · Recruiting
Novartis Investigative Site
Zhengzhou, Henan, China · Recruiting
Novartis Investigative Site
Marseille, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Poitiers, France · Recruiting
Novartis Investigative Site
Strasbourg, France · Recruiting
Novartis Investigative Site
Erlangen, Germany · Recruiting
Novartis Investigative Site
Hamburg, Germany · Recruiting
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany · Recruiting
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary · Recruiting
Novartis Investigative Site
Padova, PD, Italy · Recruiting
Novartis Investigative Site
Roma, RM, Italy · Recruiting
Novartis Investigative Site
Fukuoka, Japan · Recruiting
Novartis Investigative Site
Saitama, Japan · Recruiting
Novartis Investigative Site
Yokohama, Kanagawa, Japan · Recruiting
Novartis Investigative Site
Utrecht, Netherlands · Recruiting
Novartis Investigative Site
Gdansk, Poland · Recruiting
Novartis Investigative Site
Wroclaw, Poland · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Bangkok, Thailand · Recruiting
Novartis Investigative Site
Bangkok, Thailand · Recruiting
Novartis Investigative Site
Hanoi, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.